Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended		9 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Statement
Revenue
Expenses:
General and administrative expenses	[1]	1,717,666	1,858,536	3,825,602	3,547,990
Research and development expenses		377,924	333,565	1,106,658	847,938
Total Operating Expenses		2,095,590	2,192,101	4,932,260	4,395,928
Accretion expense	[2]		307,216	879,416	901,299
Change in fair value of derivative liabilities	[3]		125,353	20,588	714,453
Net loss before income taxes		(2,095,590)	(2,624,670)	(5,832,264)	(6,011,680)
Income taxes
Net loss		(2,095,590)	(2,624,670)	(5,832,264)	(6,011,680)
Translation adjustment		(23,424)	(24,635)	(193,771)	(185,057)
Comprehensive loss		$ (2,119,014)	$ (2,600,035)	$ (6,026,035)	$ (6,196,737)
Loss per share, basic and diluted		$ (0.068)	$ (0.100)	$ (0.186)	$ (0.236)
Weighted average number of common shares outstanding		30,799,342	26,162,293	31,374,911	25,427,620

[1] See Notes 7, 8, and 9

[2] Including day one derivative loss; See Note 5

[3] See Note 6